Wali Qayoumi, MD
Neurology · San Diego, CANPI 1093178220
Payments from drug & device makers
What this record shows
This record is dominated by grants: $87,710 of the $87,993 with a category attached, or 99.7%. Biogen accounts for 99.8% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2020 at $87,710 and has fallen 99.9% since, to $51 in 2025. Among neurology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 9 payments — averaging $9776.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$88K
- Amgen$54
- Tanabe Pharma America, Inc.$28
- Johnson & Johnson$23
- NS Pharma, Inc.$19
- Cadwell Industries, Inc$17
- plus $14 from 1 others
Across 4 payments — averaging $9828.45 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Argenx US, Inc.$39K
What the payments were for
- Grants$87,710100%
- Food & beverage$2820%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 2 | $87,837 |
| Amgen | 2 | $54 |
| Tanabe Pharma America, Inc. | 1 | $28 |
| Johnson & Johnson | 1 | $23 |
| NS Pharma, Inc. | 1 | $19 |
| Cadwell Industries, Inc | 1 | $17 |
| Eisai Inc. | 1 | $14 |
How this compares
$87,993 in reported general payments places this provider in the 90th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Radicava OrsEdaravone | 12 | $153,732 |
| Azathioprine | 33 | $3,314 |
| Pyridostigmine Bromide | 25 | $2,160 |
| Gabapentin | 52 | $1,710 |
| Riluzole | 17 | $1,210 |
| Levetiracetam | 27 | $935 |
| Pregabalin | 17 | $474 |
| Prednisone | 27 | $445 |
| Topiramate | 16 | $410 |
| Duloxetine Hcl | 11 | $252 |
| Atorvastatin Calcium | 20 | $237 |
| Sumatriptan Succinate | 32 | $209 |
Paid to pharmacies, not to this prescriber.
Other neurology in San Diego
- Chamindra LavertySan Diego$662K
- Hossein AnsariSan Diego$377K
- Revere KinkelSan Diego$266K
- Andrew BlumenfeldCarlsbad$4.9M
- Khashayar DashtipourLoma Linda$3.3M
- Regina BerkovichWest Hollywood$3M
- Daniel BandariNewport Beach$2.6M
- Perry ShiehLos Angeles$2.4M
- Sandeep ThakkarIrvine$2M
- David LiebeskindLos Angeles$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.